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Abstract: Genetic alterations in speciﬁc driver genes lead to disrup-
tion of cellular pathways and are critical events in the instigation
and progression of hepatocellular carcinoma. As a prerequisite for
individualized cancer treatment, we sought to characterize the land-
scape of recurrent somatic mutations in hepatocellular carcinoma.
We performed whole exome sequencing on 87 hepatocellular carci-
nomas and matched normal adjacent tissues to an average coverage
of 59. The overall mutation rate was roughly 2 mutations per Mb,
with a median of 45 non-synonymous mutations that altered the
amino acid sequence (range 2–381). We found recurrent mutations
in several genes with high transcript levels: TP53 (18%), CTNNB1
(10%), KEAP1 (8%), C16orf62 (8%), MLL4 (7%) and RAC2 (5%). Signif-
icantly affected gene families include the nucleotide-binding domain
and leucine rich repeat containing family, calcium channel subunits,
and histone methyltransferases. In particular, the MLL family of
methyltransferases for histone H3 lysine 4 were mutated in 20% of
tumors. Conclusion: The NFE2L2-KEAP1 and MLL pathways are
recurrently mutated in multiple cohorts of hepatocellular carcinoma.
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Abstract: Hepatocellular carcinoma (HCC) is one of the most deadly
cancers worldwide and has no effective treatment, yet the molecular
basis of hepatocarcinogenesis remains largely unknown. Here we
report ﬁndings from a whole-genome sequencing (WGS) study of
88 matched HCC tumor/normal pairs, 81 of which are Hepatitis B
virus (HBV) positive, seeking to identify genetically altered genes
and pathways implicated in HBV-associated HCC. We ﬁnd beta-cate-
nin to be the most frequently mutated oncogene (15.9%) and TP53
the most frequently mutated tumor suppressor (35.2%). The Wnt/
beta-catenin and JAK/STAT pathways, altered in 62.5% and 45.5% of
cases, respectively, are likely to act as two major oncogenic drivers
in HCC. This study also identiﬁes several prevalent and potentially
actionable mutations, including activating mutations of Janus kinase
1 (JAK1), in 9.1% of patients and provides a path toward therapeutic
intervention of the disease. 2013 European Association for the Study of the Liver. Published
by Elsevier B.V.
Like other cancers, hepatocellular carcinoma (HCC) could be
considered as an acquired genetic disorder deﬁned by an accu-
mulation of somatic genetic alterations in tumor hepatocytes
[1]. Recently, several technological breakthroughs were per-
formed and now we can decode the whole sequence of an indi-
vidual or of tumor genomes in a few days exploring more than
20,000 coding genes. Following this technological revolution, sev-
eral pioneering studies have reﬁned our knowledge of the muta-
tional landscape and the related signaling pathway involved in
liver carcinogenesis (Fig. 1) [2–6]. First, they have conﬁrmed that
activation of the Wnt/b-catenin pathway was the main oncogenic
pathway in HCC with recurrent mutations of CTNNB1 (coding for
b-catenin, 11–32%) and AXIN1 (15%) [2–4,7]. Cell cycle regulatory
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Fig. 1. Major pathways altered in hepatocellular carcinoma. Signaling pathways recurrently mutated in HCC are shown in the right panel. Oncogenes are indicated in red
and tumor-suppressor genes in blue with percentages of alterations.
JOURNAL OF HEPATOLOGYgenes were also frequently altered. In addition to the well-known
alterations in TP53 and CDKN2A [7], next generation studies have
identiﬁed new recurrent inactivating mutations of IRF2 (5%) [2],Journal of Hepatology 201leading to a functional inactivation of TP53, and of ATM (5%)
[3], a protein involved in cell cycle regulation and DNA damage
repair. Moreover, sequencing analyses revealed frequent4 vol. 60 j 224–226 225
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alterations in genes coding for proteins involved in chromatin
structure and maintenance. In particular, recurrent somatic
mutations inactivating ARID1A and ARID2 were identiﬁed in
around 10% of HCC [2–4,6]. ARID1A and ARID2 belong to the chro-
matin remodeling gene family, encoding subunits of SWI/SNF
complexes and are considered tumor suppressor genes although
they are altered in several other cancer types. Another pivotal sig-
naling pathway identiﬁed by next generation sequencing was the
activation of the NRF2/KEAP1 pathway. NRF2 (coded by NFE2L2)
is a transcription factor that is physiologically degraded by the
proteasome in a complex with KEAP1 and CUL3. When activated
by increase of reactive oxygen species or by mutations identiﬁed
in 6% of HCC [2], NRF2 dissociates from KEAP1, translocates to the
nucleus and activates the transcription of antioxidant genes
(Fig. 1). The antioxidant response gives proliferative and survival
advantages to tumor cells. Finally, activating mutations of PIK3CA,
FGF19 ampliﬁcation and inactivating mutations of RPS6KA3 are
also recurrent genetic alterations in HCC, leading to a constitutive
activation of PI3K/Akt/mTOR and Ras/Raf/MAP kinase pathways
[2,3]. However, these seminal next generation studies were lim-
ited by the small number of samples analyzed (from 10 to 27).
In two recent publications, large series of HCC cases were ana-
lyzed [8,9]. In the ﬁrst publication, Clearly et al. usedwhole exome
sequencing (exploring the entire coding sequence of the genome)
of 80 HCC and they found a mean number of 66 mutations per
tumor [8]. This value is in the middle range of mutation solid
tumors that vary from 4mutations per samples for pediatric rhab-
doid tumors to 200 in melanoma and lung cancer [1]. It indicates
that accumulation of several somatic genetic alterations is
required during liver carcinogenesis. Among them, functional
mutations in driver genes (directly involved in carcinogenesis)
should be distinguished from the stochastic background of muta-
tions in passenger genes. As pivotal driver genes, Clearly et al. con-
ﬁrmed frequent alterations of TP53 (18% of the cases) and CTNNB1
(10% of the cases) in hepatocarcinogenesis [8]. They also identiﬁed
recurrent mutations inMLL (Myeloid/Lymphoid or Mixed-Lineage
Leukemia, 2% of mutations),MLL2 (4.5%),MLL3 (1%) andMLL4 (7%)
[8]. These genes belong to the histone methylation writer gene
family and encode H3K4 methyltransferases that are involved in
methylation, acetylation and remodeling of nucleosomes (Fig. 1).
Interestingly, recurrent hepatitis B virus integration targeting
MLL4 has also been recently described [5]. Together with ARID1A
and ARID2mutations, these data reinforce the link between cancer
genome defects and epigenetic alterations in liver tumorigenesis.
Finally, Clearly et al. identiﬁed inactivating mutations of KEAP1 in
8% of the cases that are mutually exclusive of NFE2L2 mutations
and allow the activation of the antioxidant gene response [8]. In
the second publication, Kan et al. analyzed 88 HCC, mainly related
toHBV infection, usingwholegenomesequencing [9]. In this study,
the authors conﬁrmed most of the previous results but they also
enlightened frequent activations of the JAK-STAT pathway with
activatingmutationsof JAK1 (9.1%), a JAK1/2 inhibitor [9].Whereas
these resultswarrant validation inHCC of other etiologies, they are
promising for patient care because JAK1 activations are targetable
by ruxolitinib.
In conclusion, both studies have reﬁned our understanding of
the HCC genome and they revealed new recurrent somatic muta-
tions in putative driver genes. But what are the next steps in the
ﬁeld of HCC genomics? First, new insights have emerged from
non-coding tumor sequences: we recently described somatic
mutations in the promoter of the telomerase reverse transcrip-226 Journal of Hepatology 201tase (TERT) gene [10]. Now, these mutations represent the most
frequent genetic alterations in HCC (59%) and the ﬁrst recurrent
genetic alterations in cirrhotic preneoplastic lesions (25%). TERT
promoter mutations increase the promoter activity and lead to
an increased transcription of telomerase. We can assume that
other driver genetic alterations will be discovered in the dark
matter of the genome. Next, among the huge number of genes
mutated in the cancer genome, functional analysis will be war-
ranted to understand the consequences for tumorigenesis and
for targeted treatment. Moreover, data generated by massive par-
allel sequencing have to be integrated with transcriptomic,
methylome analysis, proteomic, and metabolomic in order to
capture the full complexity of liver cancer. Finally, next genera-
tion sequencing will be available very soon routinely at hospitals
and a huge effort has to be made to translate this knowledge into
a new paradigm of personalized clinical care for HCC patients.Financial support
This work was supported by the INCa with the ICGC project, the
PAIR-CHC project NoFLIC (funded by INCa and Association pour la
Recherche sur le Cancer, ARC), the Réseau national CRB Foie, HEP-
TROMIC (FP7) and ARC (grant n3194). J.-C.N. is supported by a
fellowship from the INCa.Conﬂicts of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.References
[1] Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, Kinzler KW.
Cancer genome landscapes. Science 2013;339:1546–1558.
[2] Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al.
Integrated analysis of somatic mutations and focal copy-number changes
identiﬁes key genes and pathways in hepatocellular carcinoma. Nat Genet
2012;44:694–698.
[3] Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, et al.
Whole-genome sequencing of liver cancers identiﬁes etiological inﬂuences
on mutation patterns and recurrent mutations in chromatin regulators. Nat
Genet 2012;44:760–764.
[4] Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, et al. Exome sequencing of
hepatitis B virus-associated hepatocellular carcinoma. Nat Genet
2012;44:1117–1121.
[5] Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, et al. Genome-wide survey of
recurrent HBV integration in hepatocellular carcinoma. Nat Genet
2012;44:765–769.
[6] Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, et al. Inactivating
mutations of the chromatin remodeling gene ARID2 in hepatocellular
carcinoma. Nat Genet 2011;43:828–829.
[7] Nault JC, Zucman-Rossi J. Genetics of hepatobiliary carcinogenesis. Semin
Liver Dis 2011;31:173–187.
[8] Cleary SP, Jeck WR, Zhao X, Kuichen, Selitsky SR, Savich GL, et al. Identiﬁ-
cation of driver genes in hepatocellular carcinoma by exome sequencing.
Hepatology 2013, in press.
[9] Kan Z, Zheng H, Liu X, Li S, Barber T, Gong Z, et al. Whole genome sequencing
identiﬁes recurrent mutations in hepatocellular carcinoma. Genome Res
2013;23:1422–1433.
[10] Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac Sage P, Laurent C, et al. High
frequency of telomerase reverse-transcriptase promoter somatic mutations
in hepatocellular carcinoma and preneoplastic lesions. Nat Commun
2013;4:2218.4 vol. 60 j 224–226
